Drug intelligence / Profile preview

5-fluorouracil + cyclophosphamide + doxorubicin + medroxyprogesterone acetate

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intramuscular, Oral, Intravenous

Overview

This is a combination chemotherapy regimen consisting of three cytotoxic agents (5-fluorouracil, cyclophosphamide, and doxorubicin/adriamycin) plus a hormonal therapy agent (medroxyprogesterone acetate). The regimen has been studied primarily for the treatment of metastatic breast cancer. In clinical trials, medroxyprogesterone acetate was administered at high doses (500 mg/day intramuscularly for 21 days, followed by either 500 mg/week intramuscularly or 300 mg/day orally) in combination with the standard FAC regimen.

Other names: FAC plus high-dose medroxyprogesterone acetate

Targets

TOP2A (DNA topoisomerase II)PR (Progesterone receptor)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on 5-fluorouracil + cyclophosphamide + doxorubicin + medroxyprogesterone acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + doxorubicin + medroxyprogesterone acetate.

Explore the full profile